Abstract
The growth of the human female breast is clearly under endocrine control. In the absence of stimulatory hormones, the breast remains rudimentary whilst major development normally only occurs at times of increased hormone production such as puberty and pregnancy. It is, therefore, not surprising that certain breast cancers should also require hormones for their continued growth. Whilst polypeptide hormones are capable of influencing events within breast cancers, (Dilley and Kister, 1975, Leung and Shiu, 1981) the most convincing evidence for the involvement of endocrine agents is for steroid hormones, particularly oestrogens. This includes the observations that, a) the growth of cell lines of human breast cancer may be stimulated by oestrogen both in culture (Butler et al, 1981, Benz et al, 1983) and in immunosuppressed animals (Shafie 1980, Seibert et al, 1983); b) the administration of oestrogen to breast cancer patients with metastatic deposits in bone may cause increased urinary calcium excretion due to accelerated tumour growth (Pearson et al, 1954); c) oestrogen deprivation therapy causes regression of breast cancers in about one-third of patients with advanced disease (Henderson and Canellos, 1980); d) these effects are invariably associated with tumours which possess receptors for oestrogen (Jensen et al, 1974, McGuire et al, 1975). Endocrine intervention therefore represents a major treatment option for advanced breast cancer especially against tumours which are rich in oestrogen receptors.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amarant, T., Fridkin, M., and Koch Y., 1982, Luteinizing hormone-releasing hormone and thyrotropin-releasing hormone in human and bovine milk, Europ J Biochem, 127:647.
Bardon, S., Vignon, F., Chalbos, D., and Rochefort, H., 1985, RU 486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor, J Clin Endocrinol Metab, 60:692.
Belchetz, P.E., Plant, T.M., Nakai, Y., Keogh, E.J., and Knobil, E., 1978, Hypophyseal responses to continuous and intermittent delivery of hypothalamic gonadotrophin-releasing hormone, Science, 202:631.
Belisle, S., Guevin, J-F., Bellabarba, D., and Leloux, J-G., 1984, Luteinizing hormone-releasing hormone binds to enriched human placental membranes and stimulates in vitro the synthesis of bioactive human chorionic gonadotropin, J Clin Endocrinol Metab, 59:119.
Benz, C., Cadman, E., Givin, J., Wu, T., Amara, J., Eisenfeld, A., and Dannies, P., 1983, Tamoxifen and 5-fluoroucil in breast cancer: Cytotoxic synergism in vitro, Cancer Res., 43:5298.
Bergquist, C., Nillius, S.J., Wide, L., and Lindgren, A., 1981, Endometrial patterns in women on chronic luteinizing hormone-releasing agonist treatment for contraception, Fert Steril, 36:339.
Bergquist, C., Nillius, S.J., and Wide, L., 1982a, Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women, Fert Steril, 38:190.
Bergquist, C., Nillius, S.J., and Wide, L., 1982b, Failure of positive feedback of oestradiol during chronic intranasal luteinizing hormone-releasing hormone agonist treatment, Clin Endocrinol, 16:147.
Bramley, T.A., Menzies, G.S., and Baird, D.T., 1985, Specific binding of LHRH and an agonist to human corpus luteum homogenates: Characterization, properties and luteal phase levels, J Clin Endocrinol Metab, 41:in press.
Butler, W.B., Kelsey, W.H., and Goran, N., 1981, Effects of serum and insulin on the sensitivity of the human breast cancer cell line MCF-7 to estrogen and antiestrogens, Cancer Res, 41:82.
Cailleau, R., Young, R., Olive, M., and Reeve, W.J., 1974, Breast tumour cell lines from pleural effusions, JNCI, 53:661.
Clayton, R.N., Harwood, J.P., and Catt, K.J., 1979, Gonadotropin-releasing hormone analogue binds to luteal cells and inhibits progesterone production, Nature, 282:90.
Corbin, A., 1982, From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumour agents, Yale J Biol Med, 55:27.
Currie, A.J., Fraser, H.M., and Sharpe, R.M., 1981, Human placental receptors for luteinizing hormone releasing hormone, Biochem Biophys Res Commun, 99:332.
Dilley, W.G., and Kister, S.J., 1975, In vitro stimulation of human breast tissue by human prolactin, JNCI, 55:35.
Eidne, K.A., Flanagan, C.A., and Millar, R.P., 1985, Gonadotropin-releasing hormone binding sites in human breast carcinoma, Science, in press.
Fraser, H.M., and Sandow, J., 1985, Suppression of follicular maturation by infusion of a luteinizing hormone releasing hormone agonist starting during the luteal phase in the stumptailed macaque monkey, J Clin Endocrinol Metab, 60:579.
Furr, B.J.A., and Nicholson, R.I., 1982, Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer, J Reproduct Fertil, 64:529.
Hardt, W., and Schmidt-Gollwitzer, M., 1983, Sustained gonadal suppression in fertile women with the LHRH agonist, buserelin, Clin Endocrinol, 19:613.
Harvey, H.A., Lipton, A., and Max, D.T., 1984, LHRH analogs for human mammary carcinoma in: “LHRH and its Analogs, Contraceptive and Clinical Application”, B.H. Vickery, J.J. Nestor and E.S.E. Hafez, eds, MTP, Lancaster, p 329.
Henderson I.C., and Canellos, G.P., 1980, Cancer of the breast: the past decase, N Engl J Med, 302:17, 78.
Jensen, E.V., Mohlar, S., Gorell, T.A., and De Sombre, E.R., 1974, The role of estrophilin in oestrogen action, Vit and Horm, 32:89.
Keydar, I., Chen, L., Karby, S., Weiss, F.R., Delarea, J., Radu, M., Chaitcik, S., and Brenner, H.J., 1979, Establishment of a cell line of human breast carcinoma origin, Eur J Cancer, 15:659.
Khodr, G., and Siler-Khodr, T.M., 1978, The effect of luteinizing hormone-releasing factor on human chorionic gonadotrophin secretion, Fert Steril, 30:301.
Klijn, J.G.M. and de Jong, F.H., 1982, Treatment with a luteinizing-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer, The Lancet, i:1213.
Klijn, J.G.M., and de Jong, F.H., 1984, Long-term treatment with the LHRH-agonist buserelin (HOE 766) for metastatic breast cancer in single and combined drug regimens, in: “LHRH and its analogues”, F. Labrie, A. Belanger and A. Dupont, eds, Elsevier Science, Amsterdam, New York, p 425.
Klijn, J.G.M., de Jong, F.H., Blankenstein, M.A., Docter, R., Alexieva-Figusch, J., Blonk-van-der Wijst, J., and Lamberts, W.S.J., 1984, Anti-tumour and endocrine effects of chronic LHRH agonist treatment (buserelin) with or without tamoxifen in premenopausal metastatic breast cancer, Breast Cancer Res and Treat, 4:209.
Lamberts, S.W.J., Timmers, J.M., Oosterom, R., Verleun, J., Rommerts, F.G., and de Jong, F.H., 1982, Testosterone secretion by cultured arrhenoblastoma cells: Suppression by a luteinizing hormone-releasing hormone agonist, J Clin Endocrinol Metab, 54:450.
Leung, C.K.H., and Shiu, R.P.C., 1981, Required presence of both estrogen and pituitary factors for the growth of human breast cancer cells in athymic nude mice, Cancer Res, 41:546.
Lippman, M., 1981, Hormonal regulation of human breast cancer cells in vitro, in: “Banbury Report No 8 Hormones and Breast Cancer”, M.C. Pike, P.K. Siiteri and C.W. Welsch, eds, Cold Spring Harbor Laboratory, U.S.A., p 171.
Lippman, M., Bolan, G., and Huff, K., 1976a, The effects of estrogens and antioestrogens on hormone-responsive human breast cancer in long-term tissue culture, Cancer Res, 36:4595.
Lippman, M.E., Bolan, G., and Huff, K., 1976b, The effect of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture, Cancer Res, 36:4602.
Lippman, M.E., Bolan, G., and Huff, K., 1976c, The effects of androgens and anti-androgens on hormone-responsive human breast cancer in long-term tissue culture, Cancer Res, 36, 4610.
McGuire, W.L., Pearson, O.H., and Segaloff, A., 1975, Predicting hormone responsiveness in human breast cancer, in: “Oestrogen receptors in human breast cancer”, W.L. McGuire, P.P. Carbone and E.D. Vollmer, eds, Raven Press, New York, p 17.
Miller W.R., Scott, W.N., Morris, R., Fraser, H.M., and Sharpe, R.M., 1985, Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing agonist, Cancer Res, 36:3610.
Nicholson, R.I,, and Maynard, P.V., 1979, Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist, Brit J Cancer, 39:268.
Nicholson, R.I., Walker, K.J., Turkes, A., Turkes, A.O., Dyas, J., Blarney, R.W., Campbell, R.F., Robinson, M.R.G., and Griffiths, K., 1984, Therapeutic significance and the mechanism of action of the LHRH agonist ICI 118630 in breast and prostatic cancer, J Steroid Biochem, 20:129.
Nicholson, R.I,, Walker, K.J., Turkes, A., Dyas, J., Plowman, P.N., Williams, M., and Blarney, R.W., 1985, Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer, J Steroid Biochem, in press.
Pearson, O.H., West, C.D., Hollander, V.P., and Treves, N.E., 1954 Valuation of endocrine therapy for advanced breast cancer, J.A.M.A., 154:234.
Petroza, E., Vilchez-Martinex, J.A., Coy, D.H., Arumura, A., and Schally, A.V., 1980, Reduction of LHRH pituitary and estradiol uterine binding sites by a superactive analog of luteinizing hormone-releasing hormone, Biochem Biophys Res Commun, 95:1056.
Popkin, R., Bramley, T.A., Currie, A., Shaw, R.W., Baird, D.T., and Fraser, H.M., 1983, Specific binding of luteinizing hormone-releasing hormone to human luteal tissue, Biochem Biophys Res Commun, 114:750.
Sandow, J., von Rechenberg, W., Jerzabek, G., and Stoll, W., 1978, Pituitary gonadotrophin-inhibition by a highly active analog of luteinizing hormone-releasing hormone, Fert Steril, 30:205.
Schmidt-Gollwitzer, M., Hardt, W., Schmidt-Gollwitzer, K., von der Ohe, M., and Nevinng-Stickel, J., 1981, Influence of the LHRH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?, Contraception, 23:187.
Schmidt-Gollwitzer, M., Hardt, W., Schmidt-Gollwitzer, K., and von der Ohe, M., 1982, The contraceptive use of buserelin, a potent LHRH agonist: clinical and hormonal findings, in: “LHRH peptides as male and female contraceptives”, G. Zatuchni, ed, Lippincott, U.S.A., p 199.
Seeburg, P.H., and Adelman, J.P., 1984, Characterization of cDNA for precursor of human luteinizing hormone-releasing hormone, Nature, 311:666.
Seibert, K., Shafie, S.M., Triche, T.J., Whang-Peng, J.J., O’Brien, S.J., Toney, J.H., Huff, K.K., and Lippman, M.E., 1983, Clonal variations of MCF-7 breast cancer cells in vitro and in athymic nude mice, Cancer Res, 43:2223.
Seppala, M., and Wahlstrom, T., 1980, Identification of luteinizing hormone-releasing factor and alpha subunit of glycoprotein hormones in ductal carcinoma of the mammary gland, Int J Cancer, 26:267.
Shafie, S.M., 1980, Estrogen and growth of breast cancer:New evidence suggests indirect action, Science, 209:701.
Schally, A.V., Arimura, A., and Coy, A.H., 1980, Recent approaches to fertility control based on derivatives of LHRH, Vit and Horm, 38:257.
Schally, A.V., Redding, T.W., and Comaru-Schally, A.M., 1984, Potential use of analogs of LHRH in the treatment of hormone sensitive neoplasias, Cancer Treatment Reports 25th Anniversary Issue (NIH), 68:No 1.
Sharpe, R.M., and Fraser, H.M., 1980, Leydig cell receptors for luteinizing hormone releasing hormone and its agonists and their modulation by administration or deprivation of the releasing hormone, Biochem Biophys Res Commun, 45:256.
Shiu, R.P.C., and Paterson, J.A., 1984, Alteration in cell shape, adhesion and lipid accumulation in human breast cancer cell (T-47D) by human prolactin and growth hormone, Cancer Res, 44:1178.
Sundaram, K., Cao, Y-C., Wang, N-G., Bardin, C.W., Rivier, J., and Vale, W., 1981, Inhibition of the action of sex steroids by gonadotropin-releasing hormone (GnRH) agonists: a new biological effect, Life Sciences, 28:83.
Tan, L., and Rousseau, P., 1983, The chemical identity of the immuno-reactive LHRH-like peptide biosynthesized in the human placenta, Biochem Biophys Res Commun, 109:1061.
Thomas, D.B., 1983, Factors that promote the development of human breast cancer, Environmental Health Perspectives, 50:209.
Tureck, R.W., Mastroianni, L., Blasco, L., and Strauss, J.R., 1982, Inhibition of human granulosa cell progesterone secretion by a gonadotropin-releasing hormone agonist, J Clin Endocrinol Metab, 54:1078.
Wiznitzer, I., and Benz, C., 1984, Direct growth inhibiting effects of the prolactin antagonists Buserelin and Pergolide on human breast cancer, Proc Ann Am Assoc Cancer Res, 25:208.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Miller, W.R., Scott, W.N., Morris, R., Fraser, H.M., Sharpe, R.M. (1986). Direct Effects of LHRH and Agonists on Human Breast Cancer Cells. In: Fink, G., Harmar, A.J., McKerns, K.W. (eds) Neuroendocrine Molecular Biology. Biochemical Endocrinology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5131-3_41
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5131-3_41
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5133-7
Online ISBN: 978-1-4684-5131-3
eBook Packages: Springer Book Archive